FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563679085> ?p ?o ?g. }

• W2563679085 endingPage "5519" @default.
• W2563679085 startingPage "5519" @default.
• W2563679085 abstract "5519 Background: Cetuximab is commonly used in combination with either chemotherapy or radiation in the treatment of HNC, although the optimal way to integrate cetuximab with concurrent chemoradiation (CRT) remains unclear. We explored the addition of cetuximab to induction chemotherapy and two established CRT platforms in a randomized phase II trial. Methods: Patients with locoregionally advanced HNC were treated with cetuximab, carboplatin, paclitaxel induction chemotherapy for 2 cycles. Patients were randomized to A: cetuximab, 5-FU, hydroxyurea, and hyperfractionated week-on week-off RT (72-74Gy) (CetuxFHX), or B: cetuximab, cisplatin, accelerated radiation with concomitant boost (CetuxPX)(72Gy). Primary endpoints were 1- and 2-year progression-free (PFS), and overall survival (OS). Results: 110 patients with locoregionally advanced HNC (108 with Stage IV) were enrolled. 57.3% of patients had oropharyngeal (OP) primaries (A: 49%, B: 66%, p16 staining is pending). Induction response rate was 91.8%. 99.1% of patients developed a rash (≥grade 3 in 16.4%); ≥grade 3 neutropenia developed in 36.3% of patients. Overall 1- and 2-year survival rates were 98.3% and 89.5% in CetuxFHX, and 94.2% and 91.4% in CetuxPX arm, with 21.1months median follow-up (not statistically significant, p=0.27, logrank test). Progression free survival at 1 and 2 years was 86.0% and 82.3% in CetuxFHX, and 95.9% and 89.7% in CetuxPX (p=0.18). Grade ≥3 mucositis was present in 91.1%(A) and 94.3%(B) of patients; grade ≥3 dermatitis in 82.1% and 50.9% of patients. 95% of patients completed therapy. Treatment failures occurred in both OP and non-OP tumors. Conclusions: Cetuximab-based induction chemotherapy is well tolerated and active. Cetuximab can safely be integrated with both FHX and cisplatin based CRT with acceptable toxicities. Survival is favorable on both study arms suggesting that either platform could be investigated further. Data on HPV versus non-HPV-related tumors will be available." @default.
• W2563679085 created "2017-01-06" @default.
• W2563679085 creator A5001334189 @default.
• W2563679085 creator A5002557162 @default.
• W2563679085 creator A5008467612 @default.
• W2563679085 creator A5037253945 @default.
• W2563679085 creator A5038481817 @default.
• W2563679085 creator A5045590297 @default.
• W2563679085 creator A5055165247 @default.
• W2563679085 creator A5063904421 @default.
• W2563679085 creator A5066986846 @default.
• W2563679085 creator A5070574602 @default.
• W2563679085 creator A5077701955 @default.
• W2563679085 creator A5082413734 @default.
• W2563679085 date "2011-05-20" @default.
• W2563679085 modified "2023-10-17" @default.
• W2563679085 title "A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC)." @default.
• W2563679085 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.5519" @default.
• W2563679085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28021429" @default.
• W2563679085 hasPublicationYear "2011" @default.
• W2563679085 type Work @default.
• W2563679085 sameAs 2563679085 @default.
• W2563679085 citedByCount "14" @default.
• W2563679085 countsByYear W25636790852012 @default.
• W2563679085 countsByYear W25636790852013 @default.
• W2563679085 countsByYear W25636790852014 @default.
• W2563679085 countsByYear W25636790852015 @default.
• W2563679085 countsByYear W25636790852017 @default.
• W2563679085 countsByYear W25636790852021 @default.
• W2563679085 crossrefType "journal-article" @default.
• W2563679085 hasAuthorship W2563679085A5001334189 @default.
• W2563679085 hasAuthorship W2563679085A5002557162 @default.
• W2563679085 hasAuthorship W2563679085A5008467612 @default.
• W2563679085 hasAuthorship W2563679085A5037253945 @default.
• W2563679085 hasAuthorship W2563679085A5038481817 @default.
• W2563679085 hasAuthorship W2563679085A5045590297 @default.
• W2563679085 hasAuthorship W2563679085A5055165247 @default.
• W2563679085 hasAuthorship W2563679085A5063904421 @default.
• W2563679085 hasAuthorship W2563679085A5066986846 @default.
• W2563679085 hasAuthorship W2563679085A5070574602 @default.
• W2563679085 hasAuthorship W2563679085A5077701955 @default.
• W2563679085 hasAuthorship W2563679085A5082413734 @default.
• W2563679085 hasConcept C121608353 @default.
• W2563679085 hasConcept C126322002 @default.
• W2563679085 hasConcept C143998085 @default.
• W2563679085 hasConcept C2776611710 @default.
• W2563679085 hasConcept C2776694085 @default.
• W2563679085 hasConcept C2778239845 @default.
• W2563679085 hasConcept C2778496288 @default.
• W2563679085 hasConcept C2779384505 @default.
• W2563679085 hasConcept C2779998722 @default.
• W2563679085 hasConcept C2781451048 @default.
• W2563679085 hasConcept C526805850 @default.
• W2563679085 hasConcept C71924100 @default.
• W2563679085 hasConceptScore W2563679085C121608353 @default.
• W2563679085 hasConceptScore W2563679085C126322002 @default.
• W2563679085 hasConceptScore W2563679085C143998085 @default.
• W2563679085 hasConceptScore W2563679085C2776611710 @default.
• W2563679085 hasConceptScore W2563679085C2776694085 @default.
• W2563679085 hasConceptScore W2563679085C2778239845 @default.
• W2563679085 hasConceptScore W2563679085C2778496288 @default.
• W2563679085 hasConceptScore W2563679085C2779384505 @default.
• W2563679085 hasConceptScore W2563679085C2779998722 @default.
• W2563679085 hasConceptScore W2563679085C2781451048 @default.
• W2563679085 hasConceptScore W2563679085C526805850 @default.
• W2563679085 hasConceptScore W2563679085C71924100 @default.
• W2563679085 hasIssue "15_suppl" @default.
• W2563679085 hasLocation W25636790851 @default.
• W2563679085 hasOpenAccess W2563679085 @default.
• W2563679085 hasPrimaryLocation W25636790851 @default.
• W2563679085 hasRelatedWork W1481820868 @default.
• W2563679085 hasRelatedWork W151172257 @default.
• W2563679085 hasRelatedWork W1555202011 @default.
• W2563679085 hasRelatedWork W2007727361 @default.
• W2563679085 hasRelatedWork W2410193585 @default.
• W2563679085 hasRelatedWork W2471989939 @default.
• W2563679085 hasRelatedWork W2954897945 @default.
• W2563679085 hasRelatedWork W3165150305 @default.
• W2563679085 hasRelatedWork W4206824298 @default.
• W2563679085 hasRelatedWork W4302319510 @default.
• W2563679085 hasVolume "29" @default.
• W2563679085 isParatext "false" @default.
• W2563679085 isRetracted "false" @default.
• W2563679085 magId "2563679085" @default.
• W2563679085 workType "article" @default.